Welcome to our dedicated page for Greenwich LifeSciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich LifeSciences stock.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company dedicated to the development of groundbreaking immunotherapies aimed at preventing breast cancer recurrences. The company's flagship product, GP2, is an immunotherapy designed to stimulate the body's immune system to target and eliminate HER2/neu-expressing cancer cells, particularly in patients who have already undergone surgery for breast cancer.
GP2 leverages the HER2/neu transmembrane peptide to elicit a targeted immune response, providing a promising approach to cancer treatment. Another significant component of their pipeline is the GM-CSF Immunoadjuvant, which has shown potential in enhancing monocyte and neutrophil cytotoxicity against melanoma tumor cells, as well as boosting activity-dependent cellular cytotoxicity against targets coated with anti-ganglioside antibodies.
The company’s ongoing clinical trials are a testament to its commitment to innovation and excellence in cancer treatment. These trials are being conducted in collaboration with a steering committee comprising esteemed members from various medical institutions, ensuring rigorous oversight and adherence to the highest standards of clinical research.
Greenwich LifeSciences places a strong emphasis on advancing cancer immunotherapy to selectively stimulate an individual's immune system to attack cancer cells, thereby inhibiting the spread of the disease. Their work not only focuses on breast cancer but extends to other cancer types, showcasing a broad potential for impact in oncology.
With a robust pipeline, strategic partnerships, and a clear focus on unmet medical needs, Greenwich LifeSciences is poised to be a leader in the biopharmaceutical industry. Investors and stakeholders can stay updated on the latest developments and company performance through regular news updates and reports.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) announced the commencement of commercial line filling for its immunotherapy GP2 aimed at preventing breast cancer recurrences. This milestone is part of preparations for filing a Biologics License Application (BLA) after generating three commercial lots, aiming to treat approximately 22,000 patients. The Phase III clinical trial, named FLAMINGO-01, will begin shortly, with a focus on patients with HLA-A*02. The company has engaged various partners for production and clinical support, enhancing the potential success of GP2 in the market.
Greenwich LifeSciences, Inc. (GLSI) will feature CEO Snehal Patel in an exclusive interview on Bloomberg TV's The RedChip Money Report on November 20, at 7 pm ET. The interview will cover Phase IIb clinical trial outcomes for GLSI-100, showing no metastatic breast cancer recurrences over five years. Upcoming clinical trials FLAMINGO-01 will involve 500 patients, aiming for significant event detection. The company is preparing for future data publications and highlights the impact of joining the Russell 2000.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has announced that CEO Snehal Patel will participate in Jefferies’ Annual London Healthcare Conference from November 16-19, 2021. This prestigious event is Europe's largest healthcare-focused conference, featuring top companies in the pharmaceutical and biotechnology sectors. The company is advancing its Phase III clinical trial, FLAMINGO-01, for GP2, an immunotherapy aimed at preventing breast cancer recurrence, with the trial expected to involve approximately 600 patients.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) announced the acceptance of two abstracts and posters for presentation at the San Antonio Breast Cancer Symposium (SABCS) scheduled for December 7-10, 2021. The posters will highlight data from their ongoing Phase IIb clinical trial of GLSI-100, their immunotherapy aimed at preventing breast cancer recurrence. CEO Snehal Patel emphasized the significance of this data, citing a 100% disease-free survival rate over five years. The Phase III trial, FLAMINGO-01, is set to commence, targeting approximately 500 patients.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) outlined progress on its Phase III clinical trial, FLAMINGO-01, aimed at evaluating GLSI-100, an immunotherapy for breast cancer recurrence prevention. The trial is now recruiting at over 15 large university hospitals. An open-label arm is introduced to broaden immune response data. Interim analysis is anticipated in about three years. The company is also advancing commercial manufacturing for potential regulatory submissions, enhancing prospects for conditional market approval based on positive interim findings.
Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, has released an updated corporate presentation focused on GP2, an immunotherapy to prevent breast cancer recurrences. The presentation includes a combined analysis of 5-year Phase IIb data, showcasing no recurrences in patients treated with GP2. CEO Snehal Patel highlighted interest from major institutions for potential collaborations, licensing, and expansion of clinical trials in Europe. The company plans to commence a Phase III clinical trial following promising Phase IIb results, where GP2 was well-tolerated with no serious adverse events.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has announced its partnership as a Bronze sponsor for the Susan G. Komen Race for the Cure in Houston on October 2, 2021. The company will manage a water station and actively participate in the event. This collaboration underscores Greenwich's commitment to supporting breast cancer patients and survivors. The CEO emphasized the alignment of their goal to prevent metastatic breast cancer recurrence with the mission of the Komen foundation. The event aims to raise funds for breast cancer advocacy and research.
Greenwich LifeSciences (GLSI) announced that CEO Snehal Patel will present at the Benzinga Healthcare Small-Cap Conference on September 29-30, 2021. Patel's presentation is scheduled for September 29 at 9:30 am ET. The conference will connect investors with small-cap companies and features live presentations and educational sessions. Greenwich LifeSciences is focused on developing GP2, an immunotherapy designed to prevent breast cancer recurrences. Notably, in a Phase IIb trial, GP2 showed no recurrences after five years in treated patients.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) participates in the 2021 Cantor Virtual Global Healthcare Conference from September 27-30, 2021. CEO Snehal Patel will present virtually on September 29 at 2:00 PM ET and engage in one-on-one meetings with investors. The conference features over 300 companies and a keynote by Pfizer's CEO, Albert Bourla. Greenwich develops GP2, an immunotherapy aimed at preventing breast cancer recurrence in patients post-surgery, with promising Phase IIb trial results showing no recurrences after 5 years.
Greenwich LifeSciences, Inc. (GLSI) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Snehal Patel will present on demand starting September 13 and engage in one-on-one meetings with investors. The conference will feature key industry speakers and networking opportunities. Greenwich’s main focus is on its innovative GP2 immunotherapy aimed to prevent breast cancer recurrences, supported by successful Phase IIb clinical trial results.
FAQ
What is the current stock price of Greenwich LifeSciences (GLSI)?
What is the market cap of Greenwich LifeSciences (GLSI)?
What is Greenwich LifeSciences, Inc.?
What is GP2?
What does the GM-CSF Immunoadjuvant do?
What types of cancer is Greenwich LifeSciences targeting?
Who oversees the clinical trials at Greenwich LifeSciences?
What is the significance of HER2/neu in cancer treatment?
Are there any ongoing clinical trials?
How can investors stay updated on the company?
What makes Greenwich LifeSciences' approach unique?
Where can I find more information about Greenwich LifeSciences?
